Argenx profit surges 116% as VYVGART sales hit $1.3B in record Q1
Compartilhar
Argenx (NASDAQ:ARGX) delivered a powerful start to 2026, reporting first-quarter financial results that demonstrate the accelerating commercial scale of its flagship FcRn blocker, VYVGART.
